Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

A novel method of producing 1-chloro-3-(4-chlorophenoxy)benzene can include performing hydrogenation reduction of 1-bromo-2-chloro-4-(4-chlorophenoxy)benzene or 1-bromo-4-chloro-2-(4-chlorophenoxy)benzene.

A novel method of producing 1-chloro-3-(4-chlorophenoxy)benzene can include performing hydrogenation reduction of 1-bromo-2-chloro-4-(4-chlorophenoxy)benzene or 1-bromo-4-chloro-2-(4-chlorophenoxy)benzene.

An object of the present invention is to provide a compound having an excellent rate of change in HTP caused by exposure. Another object of the present invention is to provide a liquid crystal composition formed of the compound, a cured product, an optically anisotropic body, and a reflective film.

The compound of the present invention is represented by General Formula (1).

##STR00001##

In General Formula (1), a portion where a solid line and a broken line are parallel to each other represents a single bond or a double bond.

In General Formula (1), X.sup.1 to X.sup.8 each independently represent a hydrogen atom or a monovalent substituent. However, at least one of X.sup.1, X.sup.3, X.sup.5, or X.sup.7 and at least one of X.sup.2, X.sup.4, X.sup.6, or X.sup.8 represent a substituent including a group represented by General Formula (2).

##STR00002##

In General Formula (2), Z represents a single bond or —O—. Y.sup.1 and Y.sup.2 each independently represent a hydrogen atom or a hydrocarbon group not including an aryl group. *1 and *2 represent bonding positions.

Provided in the present invention are a phenylpropionate compound, a preparation method for same, and applications. The phenylpropionate compound has the structure as represented by formula I. The phenylpropionate compound of the present invention, a pharmaceutically acceptable salt, a solvate, a prodrug, and a tautomer or stereochemical isomer or pharmaceutical composition of the compound provide improved anti-inflammatory and antiplatelet effects and, at the same time, provide an extended time window for treatment, are free of obvious side effects, safe and effective, applicable in an antithrombus, anti-inflammatory, and cerebral stroke treating medicament, and have broad application prospects.

Provided in the present invention are a phenylpropionate compound, a preparation method for same, and applications. The phenylpropionate compound has the structure as represented by formula I. The phenylpropionate compound of the present invention, a pharmaceutically acceptable salt, a solvate, a prodrug, and a tautomer or stereochemical isomer or pharmaceutical composition of the compound provide improved anti-inflammatory and antiplatelet effects and, at the same time, provide an extended time window for treatment, are free of obvious side effects, safe and effective, applicable in an antithrombus, anti-inflammatory, and cerebral stroke treating medicament, and have broad application prospects.

The present invention relates to modulators of lipoxygenase and/or cyclooxygenase enzyme. The present invention also provides compositions comprising such modulators, and methods therewith for treating lipoxygenase receptor mediated diseases.

The present invention relates to modulators of lipoxygenase and/or cyclooxygenase enzyme. The present invention also provides compositions comprising such modulators, and methods therewith for treating lipoxygenase receptor mediated diseases.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.